Erlotinib for the Treatment of Non-Small Cell Lung Cancer Technology Appraisal

May 2017

Cancer

Country of origin: UK

Erlotinib is recommended as an alternative to docetaxel for patients with non-small-cell lung cancer (NSCLC) who have already tried one chemotherapy regimen but it has not worked. Erlotinib should be used only when the manufacturer provides the drug at the same overall treatment cost as docetaxel. This cost includes the cost of giving the drug, treatments for any side effects and the cost of monitoring patients to check that treatment is working.

If the overall treatment cost is equal, specialists should discuss with patients the potential benefits and risks of erlotinib and docetaxel before deciding which treatment to use.

Erlotinib is not recommended for people with locally advanced or metastatic NSCLC who cannot take docetaxel and have already tried one chemotherapy regimen but it has not worked.

Erlotinib is not recommended for people who have already tried two chemotherapy regimens, including docetaxel, but they haven't worked.

Healthcare professionals should not stop prescribing erlotinib for people who were already taking it when the guidance was issued. These patients should be able to carry on taking erlotinib until they and their specialist decide that it is the right time to stop treatment.

'Lung cancer (non-small-cell) - erlotinib: guidance ' is available online.

Resources

Institute of Cancer Research February 2019 The Institute of Cancer Research (ICR) new website is designed to serve the needs of a wide audience: the international...
Researchers in bowel cancer discovery February 2019 Scientists have discovered how genes cause bowel cancer cells to become resistant to treatments used against the disease....
The Role And Value Of Specialist Nurses In Prostate Cancer Care January 2019 Specialist nurses may play an important role in helping to improve the experiences of patients with prostate cancer,...
Transplantation of organs from donors with a history of cancer January 2019 The Advisory Committee on the Safety of Blood, Tissues and Organs (SaBTO) reviewed evidence including the outcomes of...
inPractice® Oncology. January 2019 inPractice® Oncology is the only point-of-care clinical reference designed to meet the unique needs of specialists. Full...
Prostate cancer report January 2019 Prostate Cancer UK has launched a new report, 'Men United v Prostate Cancer: Five inequalities, five solutions', and are...
Website Helps Cancer Patients With Fertility Preservation December 2018 A website to help cancer patients learn more about how they can preserve their ability to have children has been launched...
Manual for Cancer Services: Chemotherapy Measures November 2018 Following a three month consultation period the revised chemotherapy measures were published recently for inclusion in the...
QuitMedKit counseling and treatment of tobacco dependence October 2018 Tobacco use remains the number-one preventable cause of morbidity and mortality in the United States and worldwide. So it’s...
Sublux radiology app for all medical providers October 2018 What apps are available that teach the basics of plain radiography for more than just chest X-rays and ortho trauma? Are...
Search by Keyword